Fosun Pharma enhances incentives, renews key agreements

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has announced the proposed adoption of its 2025 A Share Option Scheme and 2025 H Share RSU Scheme, designed to attract and retain talent by aligning employee interests with the company's long-term development. The A Share Option Scheme proposes granting up to 5,726,100 A Share Options, while the H Share RSU Scheme aims to grant up to 13,370,500 RSUs, including a conditional grant of 953,500 RSUs to Mr. Chen and other executive directors. Both schemes incorporate performance appraisal metrics at the Group and individual levels, ensuring incentives are tied to company success.

In parallel, the company is renewing its Financial Services Agreement with Fosun Finance and the Products/Services Mutual Supply Framework Agreement with Sinopharm. The Financial Services Agreement, effective from January 1, 2026, to December 31, 2028, outlines non-exclusive financial services with a maximum daily deposit balance of RMB2.0 bn. The Renewed Products/Services Mutual Supply Framework Agreement, also for three years from January 1, 2026, to December 31, 2028, covers mutual supply of products/services with estimated annual caps of RMB11,000 m for sales by the Group and RMB800 m for procurement.

These proposals will be presented for approval at an Extraordinary General Meeting on Thursday, October 23, 2025. Key executives and interested parties, including Mr. Chen, Ms. Guan, Mr. Wen, Mr. Wang, Mr. Liu, and Ms. Yan Jia, will abstain from voting on resolutions where they hold a material interest.